Climb Bio Inc (CLYM)

$4.78 -0.38 (-7.36%)
Market Cap 351.83M
Revenue (ttm) 0.00
Net Income (ttm) -73.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 537,800
Avg Vol 1,433,354
Day's Range N/A - N/A
Shares Out 68.18M
Stochastic %K 64%
Beta -0.16
Analysts Strong Sell
Price Target $9.60

Company Profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclo...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 857 2596
Address:
20 William Street, Suite 145, Wellesley Hills, United States
DunnoT
DunnoT Jan. 23 at 8:18 AM
$CLYM called it
0 · Reply
youspeaktome
youspeaktome Jan. 22 at 4:37 PM
$CLYM here it comes
0 · Reply
kubota2323
kubota2323 Jan. 20 at 4:00 PM
$CLYM $CRVS $MRAM legs go.
0 · Reply
kubota2323
kubota2323 Jan. 20 at 3:56 PM
$CLYM RA CAPITAL MANAGEMENT, L.P. 46.37% VANGUARD GROUP INC 1.94% Affinity Asset Advisors, LLC 1.92% Kynam Capital Management, LP 1.52% TANG CAPITAL MANAGEMENT LLC 1.48% BlackRock, Inc. 1.09% Peapod Lane Capital LLC 0.83% CANTOR FITZGERALD, L. P. 0.81% RENAISSANCE TECHNOLOGIES LLC 0.79% PRICE T ROWE ASSOCIATES INC /MD/ 0.78%
0 · Reply
kubota2323
kubota2323 Jan. 20 at 3:16 PM
$CLYM added/adding
0 · Reply
Ramanda87
Ramanda87 Jan. 10 at 8:08 PM
$CLYM 5,200 shares at an avg of $2.32 and accumulating. How high can this go 2026? $10? $20? $30? And why?
0 · Reply
MikeCaymanTrades
MikeCaymanTrades Jan. 9 at 9:24 PM
$CLYM Breakout Dec. Dropped and a huge bounce from 3.50
0 · Reply
KeviPort
KeviPort Jan. 9 at 8:38 PM
$CLYM Revenue includes service fees, so each extra gallon carries more than just commodity flow. December printed about $3.17 revenue per gallon ($8.01M / 2.53M) while units were +308% YoY. If $/gal holds while gallons stay elevated, the market starts paying for the service layer and repeatability, not “just fuel” 🚀
0 · Reply
JFais
JFais Jan. 8 at 1:00 PM
$CLYM- initial phase 2 pMN data 2H 26, initial readouts across all budoprutug and CLYM116 studies ($90M EV in writeup interesting vs comps)
0 · Reply
KingXamot
KingXamot Jan. 6 at 6:47 PM
$CLYM I acknowledge you.
0 · Reply
Latest News on CLYM
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

Jan 8, 2026, 7:00 AM EST - 22 days ago

Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2025, 7:00 AM EST - 2 months ago

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 6, 2025, 7:01 AM EST - 3 months ago

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Climb Bio to Present at Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 3 months ago

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

Oct 21, 2025, 7:00 AM EDT - 3 months ago

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Oct 17, 2025, 7:00 AM EDT - 3 months ago

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

Oct 1, 2025, 7:00 AM EDT - 4 months ago

Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

Sep 29, 2025, 7:00 AM EDT - 4 months ago

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

Sep 4, 2025, 7:00 AM EDT - 5 months ago

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 25, 2025, 2:41 PM EDT - 5 months ago

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 25, 2025, 7:00 AM EDT - 5 months ago

Climb Bio to Present at Upcoming September 2025 Investor Conferences

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 12, 2025, 7:00 AM EDT - 6 months ago

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 14, 2025, 7:00 AM EDT - 9 months ago

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Apr 1, 2025, 7:00 AM EDT - 10 months ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 11 months ago

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Mar 25, 2025, 4:05 PM EDT - 11 months ago

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Feb 24, 2025, 7:00 AM EST - 1 year ago

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 1 year ago

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Jan 9, 2025, 7:00 AM EST - 1 year ago

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Climb Bio to be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 1 year ago

Climb Bio to be Added to the Nasdaq Biotechnology Index

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Climb Bio Appoints Douglas E. Williams, Ph.D.

Nov 11, 2024, 7:00 AM EST - 1 year ago

Climb Bio Appoints Douglas E. Williams, Ph.D.

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Oct 11, 2024, 12:30 PM EDT - 1 year ago

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Oct 4, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Climb Bio to Host Virtual Investor Event on October 15, 2024

Oct 3, 2024, 10:00 AM EDT - 1 year ago

Climb Bio to Host Virtual Investor Event on October 15, 2024

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Oct 2, 2024, 9:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Eliem Therapeutics Announces Additions to its Leadership Team

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Additions to its Leadership Team

Eliem Therapeutics Reports Second Quarter Financial Results

Aug 14, 2024, 6:05 AM EDT - 1 year ago

Eliem Therapeutics Reports Second Quarter Financial Results

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28, 2024, 1:58 PM EDT - 1 year ago

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Jun 27, 2024, 4:01 PM EDT - 1 year ago

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Jul 20, 2023, 6:57 AM EDT - 2 years ago

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

Jul 20, 2023, 6:45 AM EDT - 2 years ago

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

May 11, 2023, 4:10 PM EDT - 2 years ago

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Mar 6, 2023, 4:10 PM EST - 3 years ago

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Feb 9, 2023, 4:01 PM EST - 3 years ago

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Nov 30, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Nov 14, 2022, 6:10 AM EST - 3 years ago

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Nov 8, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Eliem Therapeutics Provides Update on Pipeline Progress

Oct 5, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides Update on Pipeline Progress

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Aug 15, 2022, 6:10 AM EDT - 3 years ago

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Aug 2, 2022, 9:33 AM EDT - 3 years ago

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Eliem Therapeutics Provides ETX-810 Program Update

Aug 2, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides ETX-810 Program Update

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Jul 18, 2022, 7:00 AM EDT - 3 years ago

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

DunnoT
DunnoT Jan. 23 at 8:18 AM
$CLYM called it
0 · Reply
youspeaktome
youspeaktome Jan. 22 at 4:37 PM
$CLYM here it comes
0 · Reply
kubota2323
kubota2323 Jan. 20 at 4:00 PM
$CLYM $CRVS $MRAM legs go.
0 · Reply
kubota2323
kubota2323 Jan. 20 at 3:56 PM
$CLYM RA CAPITAL MANAGEMENT, L.P. 46.37% VANGUARD GROUP INC 1.94% Affinity Asset Advisors, LLC 1.92% Kynam Capital Management, LP 1.52% TANG CAPITAL MANAGEMENT LLC 1.48% BlackRock, Inc. 1.09% Peapod Lane Capital LLC 0.83% CANTOR FITZGERALD, L. P. 0.81% RENAISSANCE TECHNOLOGIES LLC 0.79% PRICE T ROWE ASSOCIATES INC /MD/ 0.78%
0 · Reply
kubota2323
kubota2323 Jan. 20 at 3:16 PM
$CLYM added/adding
0 · Reply
Ramanda87
Ramanda87 Jan. 10 at 8:08 PM
$CLYM 5,200 shares at an avg of $2.32 and accumulating. How high can this go 2026? $10? $20? $30? And why?
0 · Reply
MikeCaymanTrades
MikeCaymanTrades Jan. 9 at 9:24 PM
$CLYM Breakout Dec. Dropped and a huge bounce from 3.50
0 · Reply
KeviPort
KeviPort Jan. 9 at 8:38 PM
$CLYM Revenue includes service fees, so each extra gallon carries more than just commodity flow. December printed about $3.17 revenue per gallon ($8.01M / 2.53M) while units were +308% YoY. If $/gal holds while gallons stay elevated, the market starts paying for the service layer and repeatability, not “just fuel” 🚀
0 · Reply
JFais
JFais Jan. 8 at 1:00 PM
$CLYM- initial phase 2 pMN data 2H 26, initial readouts across all budoprutug and CLYM116 studies ($90M EV in writeup interesting vs comps)
0 · Reply
KingXamot
KingXamot Jan. 6 at 6:47 PM
$CLYM I acknowledge you.
0 · Reply
JFais
JFais Jan. 6 at 2:28 PM
$CLYM- Across The Biotech Universe: Climb Bio https://seekingalpha.com/instablog/440063-jonathan-faison/6244771-across-the-biotech-universe-clym?source=tweet
0 · Reply
peepthestamp
peepthestamp Jan. 2 at 9:59 AM
$CLYM -Aged well🫡
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 23 at 10:28 PM
$CLYM
0 · Reply
PaulLaurent
PaulLaurent Dec. 23 at 6:20 AM
🚀📈 Top Gainers 📈🚀AH $INEO $NMRA $OPTX $ZIM $CLYM
0 · Reply
Alidrisi
Alidrisi Dec. 23 at 5:25 AM
$CLYM +64%
0 · Reply
Ralphbeach
Ralphbeach Dec. 23 at 3:09 AM
$CLYM I was all over this in September. Opportunities are like sunrises. If you wait too long, you miss them. This is going to go a lot higher.
0 · Reply
mz101
mz101 Dec. 23 at 2:34 AM
$CLYM why the boost pm?
0 · Reply
Dandomski
Dandomski Dec. 23 at 12:59 AM
$CLYM how high will this go? Bought 2k shares at 1.98
0 · Reply
donthateme
donthateme Dec. 22 at 6:00 PM
$FJET $CLYM now moving up fast. Still low volume. Still in my $FJET for only 500 shares but up 50%! Woot woot
0 · Reply
Alidrisi
Alidrisi Dec. 22 at 6:00 PM
$CLYM + 47% ,,, still
0 · Reply
John_week
John_week Dec. 22 at 5:56 PM
$CLYM
0 · Reply